9 results on '"Lucia Motlova"'
Search Results
2. Continuous Assembly of β-Roll Structures Is Implicated in the Type I-Dependent Secretion of Large Repeat-in-Toxins (RTX) Proteins
- Author
-
Nela Klimova, Ladislav Bumba, Peter Sebo, Radovan Fišer, and Lucia Motlova
- Subjects
Protein Folding ,Bordetella pertussis ,Protein Conformation ,Bacterial Toxins ,03 medical and health sciences ,Cytosol ,0302 clinical medicine ,Bacterial Proteins ,Structural Biology ,Gram-Negative Bacteria ,Extracellular ,Secretion ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,Type I Secretion Systems ,biology ,Chemistry ,cyaA ,Variable length ,biology.organism_classification ,Cell biology ,Glycine ,Adenylate Cyclase Toxin ,030217 neurology & neurosurgery ,Bacteria - Abstract
Repeats-in-Toxin (RTX) proteins of Gram-negative bacteria are excreted through the type I secretion system (T1SS) that recognizes non-cleavable C-terminal secretion signals. These are preceded by arrays of glycine and aspartate-rich nonapeptide repeats grouped by four to eight β strands into blocks that fold into calcium-binding parallel β-roll structures. The β-rolls are interspersed by linkers of variable length and sequence and the organization of multiple RTX repeat blocks within large RTX domains remains unknown. Here we examined the structure and function of the RTX domain of Bordetella pertussis adenylate cyclase toxin (CyaA) that is composed of five β-roll RTX blocks. We show that the non-folded RTX repeats maintain the stability of the CyaA polypeptide in the Ca2+-depleted bacterial cytosol and thereby enable its efficient translocation through the T1SS apparatus. The efficacy of secretion of truncated CyaA constructs was dictated by the number of retained RTX repeat blocks and depended on the presence of extracellular Ca2+ ions. We further describe the crystal structure of the RTX blocks IV-V of CyaA (CyaA1372-1681) that consists of a contiguous assembly of two β-rolls that differs substantially from the arrangement of the RTX blocks observed in RTX lipases or other RTX proteins. These results provide a novel structural insight into the architecture of the RTX domains of large RTX proteins and support the "push-ratchet" mechanism of the T1SS-mediated secretion of very large RTX proteins.
- Published
- 2020
- Full Text
- View/download PDF
3. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors
- Author
-
Frederik L. Giesel, Yvonne Remde, Max Geerlings, Matthias Eder, Martina Benešová, Cyril Barinka, Klaus Kopka, Lucia Motlova, Ulrike Bauder-Wüst, Mareike Roscher, Martin Schäfer, Jens Cardinale, and Zora Novakova
- Subjects
0303 health sciences ,Biodistribution ,Chemistry ,urologic and male genital diseases ,medicine.disease ,01 natural sciences ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,03 medical and health sciences ,Prostate cancer ,Drug Discovery ,Cancer research ,medicine ,Molecular Medicine ,Linker ,030304 developmental biology ,Membrane antigen - Abstract
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.
- Published
- 2020
- Full Text
- View/download PDF
4. Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer
- Author
-
Liming Qiu, Jakub Ptacek, Petr Kolenko, Lucia Motlova, Shi-Jie Chen, Paloma H. Giangrande, Sven Kruspe, Dong Zhang, Barbora Havlinova, Petra Baranova, Shambhavi Shubham, Zora Novakova, Xiaoqin Zou, and Cyril Barinka
- Subjects
Glutamate Carboxypeptidase II ,Male ,AcademicSubjects/SCI00010 ,In silico ,Aptamer ,Plasma protein binding ,Biology ,urologic and male genital diseases ,Ligands ,03 medical and health sciences ,0302 clinical medicine ,Structural Biology ,Genetics ,Glutamate carboxypeptidase II ,Biomarkers, Tumor ,Humans ,Protein Interaction Domains and Motifs ,030304 developmental biology ,0303 health sciences ,Molecular Structure ,HEK 293 cells ,RNA ,Prostatic Neoplasms ,Aptamers, Nucleotide ,Small molecule ,HEK293 Cells ,030220 oncology & carcinogenesis ,Cancer cell ,Antigens, Surface ,PC-3 Cells ,Biophysics ,Protein Binding - Abstract
Prostate-specific membrane antigen (PSMA) is a well-characterized tumor marker associated with prostate cancer and neovasculature of most solid tumors. PSMA-specific ligands are thus being developed to deliver imaging or therapeutic agents to cancer cells. Here, we report on a crystal structure of human PSMA in complex with A9g, a 43-bp PSMA-specific RNA aptamer, that was determined to the 2.2 Å resolution limit. The analysis of the PSMA/aptamer interface allows for identification of key interactions critical for nanomolar binding affinity and high selectivity of A9g for human PSMA. Combined with in silico modeling, site-directed mutagenesis, inhibition experiments and cell-based assays, the structure also provides an insight into structural changes of the aptamer and PSMA upon complex formation, mechanistic explanation for inhibition of the PSMA enzymatic activity by A9g as well as its ligand-selective competition with small molecules targeting the internal pocket of the enzyme. Additionally, comparison with published protein–RNA aptamer structures pointed toward more general features governing protein-aptamer interactions. Finally, our findings can be exploited for the structure-assisted design of future A9g-based derivatives with improved binding and stability characteristics.
- Published
- 2020
5. Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors
- Author
-
Camilo Rojas, Reiji Tsukamoto, Daniel Bím, Tibor András Rokob, Takashi Tsukamoto, Zora Novakova, Gabriel Kabarriti, Cyril Barinka, Lubomír Rulíšek, Niyada Hin, Lucia Motlova, Dana Ferraris, Milos Budesinsky, Barbara S. Slusher, and Bridget Duvall
- Subjects
Glutamate Carboxypeptidase II ,Models, Molecular ,Carbamate ,Stereochemistry ,medicine.medical_treatment ,Clinical Biochemistry ,Pharmaceutical Science ,01 natural sciences ,Biochemistry ,Article ,Cell Line ,Catalytic Domain ,Drug Discovery ,Hydrolase ,medicine ,Glutamate carboxypeptidase II ,Animals ,Humans ,Urea ,Protease Inhibitors ,ddc:610 ,Molecular Biology ,Enzyme Assays ,biology ,010405 organic chemistry ,Chemistry ,Hydrogen bond ,Organic Chemistry ,Solvation ,Active site ,Hydrogen Bonding ,Stereoisomerism ,Glutamic acid ,Ligand (biochemistry) ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,biology.protein ,Quantum Theory ,Molecular Medicine ,Drosophila ,Carbamates ,Protein Binding - Abstract
Bioorganic & medicinal chemistry 27(2), 255 - 264 (2019). doi:10.1016/j.bmc.2018.11.022, A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesizedusing ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid, as a molecular template inorder to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPIIinhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potentthan compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII’s preferencefor peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealedthat ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt anearly identical binding mode while (R,S)-carbamate analog 8 containing a D-leucine forms a less extensivehydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPIIactive site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 andcompound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the proteinactive site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscorea broader range of factors that need to be taken into account in predicting ligand-protein binding affinity.These insights should be of particular importance in future efforts to design and develop GCPII inhibitors foroptimal inhibitory potency., Published by Elsevier, Amsterdam [u.a.]
- Published
- 2019
- Full Text
- View/download PDF
6. Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen
- Author
-
Hongmok Kwon, Lucia Motlova, Hyunsoo Ha, Youngjoo Byun, Hwanhee Nam, K.A. Kim, Il Minn, Nam Sangjin, Xing Yang, Doyoung Choi, Martin G. Pomper, Sang Hyun Son, Zsofia Kutil, and Cyril Barinka
- Subjects
Glutamate Carboxypeptidase II ,Plasma protein binding ,urologic and male genital diseases ,01 natural sciences ,03 medical and health sciences ,Prostate cancer ,Structure-Activity Relationship ,Antigen ,Cell Line, Tumor ,Drug Discovery ,Glutamate carboxypeptidase II ,medicine ,Structure–activity relationship ,Humans ,Urea ,Amino Acids ,IC50 ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Molecular Structure ,Chemistry ,medicine.disease ,0104 chemical sciences ,Amino acid ,010404 medicinal & biomolecular chemistry ,Biochemistry ,Antigens, Surface ,Molecular Medicine ,Pharmacophore ,Protein Binding - Abstract
Prostate-specific membrane antigen (PSMA) is an excellent biomarker for the early diagnosis of prostate cancer progression and metastasis. The most promising PSMA-targeted agents in the clinical phase are based on the Lys-urea-Glu motif, in which Lys and Glu are α-(l)-amino acids. In this study, we aimed to determine the effect of β- and γ-amino acids in the S1 pocket on the binding affinity for PSMA. We synthesized and evaluated the β- and γ-amino acid analogues with (S)- or (R)-configuration with keeping α-(l)-Glu as the S1'-binding pharmacophore. The structure-activity relationship studies identified that compound 13c, a β-amino acid analogue with (R)-configuration, exhibited the most potent PSMA inhibitory activity with an IC50 value of 3.97 nM. The X-ray crystal structure of PSMA in complex with 13c provided a mechanistic basis for the stereochemical preference of PSMA, which can guide the development of future PSMA inhibitors.
- Published
- 2020
7. Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor
- Author
-
Michal Svoboda, Timothy A. McKinsey, Cyril Bařinka, Lucia Motlova, Maria A. Cavasin, James H. Eubanks, Guangming Zhang, Sida Shen, and Alan P. Kozikowski
- Subjects
010405 organic chemistry ,Chemistry ,Organic Chemistry ,Functional capability ,Protein aggregation ,HDAC6 ,Pharmacology ,medicine.disease_cause ,01 natural sciences ,Biochemistry ,In vitro ,3. Good health ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,In vivo ,Acetylation ,Drug Discovery ,medicine ,Oxidative stress - Abstract
[Image: see text] Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date. It shows efficacy in various neurological disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress. In this work, we provide new insights into this HDAC6i by investigating the molecular basis of its interactions with HDAC6 through X-ray crystallography, determining its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to determine effective doses in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.
- Published
- 2019
8. Calcium-Driven Folding of RTX Domain β-Rolls Ratchets Translocation of RTX Proteins through Type I Secretion Ducts
- Author
-
Peter Sebo, Ilona Bibova, Cyril Barinka, Tomas Wald, Pavel Macek, Lucie Bednárová, Nela Klimova, Vaclav Veverka, Lucia Motlova, Jiri Masin, Michael Kachala, Ladislav Bumba, and Dmitri I. Svergun
- Subjects
Models, Molecular ,0301 basic medicine ,Protein Folding ,Bacterial Toxins ,Virulence ,chemistry.chemical_element ,Chromosomal translocation ,Biology ,Calcium ,medicine.disease_cause ,Bordetella pertussis ,Protein Structure, Secondary ,Cell Line ,Mice ,03 medical and health sciences ,ddc:570 ,Gram-Negative Bacteria ,medicine ,Animals ,Secretion ,Molecular Biology ,Type I Secretion Systems ,030102 biochemistry & molecular biology ,Toxin ,RTX toxin ,Cell Biology ,Cell biology ,N-terminus ,Protein Transport ,Cytosol ,030104 developmental biology ,Biochemistry ,chemistry ,Adenylate Cyclase Toxin - Abstract
Molecular cell 62(1), 47 - 62 (2016). doi:10.1016/j.molcel.2016.03.018, Calcium-binding RTX proteins are equipped with C-terminal secretion signals and translocate from the Ca$^{2+}$-depleted cytosol of Gram-negative bacteria directly into the Ca$^{2+}$-rich external milieu, passing through the “channel-tunnel” ducts of type I secretion systems (T1SSs). Using Bordetella pertussis adenylate cyclase toxin, we solved the structure of an essential C-terminal assembly that caps the RTX domains of RTX family leukotoxins. This is shown to scaffold directional Ca$^{2+}$-dependent folding of the carboxy-proximal RTX repeat blocks into β-rolls. The resulting intramolecular Brownian ratchets then prevent backsliding of translocating RTX proteins in the T1SS conduits and thereby accelerate excretion of very large RTX leukotoxins from bacterial cells by a vectorial “push-ratchet” mechanism. Successive Ca$^{2+}$-dependent and cosecretional acquisition of a functional RTX toxin structure in the course of T1SS-mediated translocation, through RTX domain folding from the C-terminal cap toward the N terminus, sets a paradigm that opens for design of virulence inhibitors of major pathogens., Published by Elsevier, Cambridge, Mass.
- Published
- 2016
- Full Text
- View/download PDF
9. 2-Aminoadipic Acid–C(O)–Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics
- Author
-
Lucia Motlova, Alan P. Kozikowski, Cyril Bařinka, Werner Tueckmantel, Zora Novakova, and Ryo Nakajima
- Subjects
0301 basic medicine ,Chemistry ,Ligand ,Stereochemistry ,Organic Chemistry ,Glutamate receptor ,2-Aminoadipic Acid ,urologic and male genital diseases ,Biochemistry ,3. Good health ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Nitrogen atom ,030220 oncology & carcinogenesis ,Drug Discovery ,Hydrolase ,Pyridine ,Glutamate carboxypeptidase II ,Linker - Abstract
[Image: see text] The design and synthesis of prostate specific membrane antigen (PSMA) ligands derived from 2-aminoadipic acid, a building block that has not previously been used to construct PSMA ligands, are reported. The effects of both the linker length and of an N-substituent of our PSMA ligands were probed, and X-ray structures of five of these ligands bound to PSMA were obtained. Among the ligands disclosed herein, 13b showed the highest inhibitory activity for PSMA. As ligand 13b can readily be radiolabeled since its fluorine atom is adjacent to the nitrogen atom of its pyridine ring, the use of this and related compounds as theranostics can be pursued.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.